Web Watch

Share this article:
Looking for credible health information on the Internet is getting much easier, if you know where and how to look for it.

While search technology has matured quite a bit over the past few years, we are still experiencing what some media insiders refer to as “crap overload.” Or, as Linda Holliday of Medical Broadcasting Company says, “We're building quite a big haystack on the Web.”

Finding the “needle” is often a difficult challenge.

It can be argued that health information seekers get a bigger benefit from search technology than most other vertical information segments. Two-thirds of all people in the US search the Internet before and after a visit to their physician according to a Nielsen/Net Ratings survey.

Almost a third of all respondents in the study said they visited a pharma site.

Google delivers a big haystack in which to find the “needle” but hasn't released a search site for healthcare. Meanwhile, newer sites like Kosmix.com and Healia.com claim to be more effective and efficient at searching for health information.

Healthline (www.healthline.com) appears to be one of the more well-rounded search portals. It does a good job of integrating content and health channels alongside its search feature. Healthline's special sauce, according to company President Dean Stephens, is its semantic taxonomy that was designed by physicians and medical informatics experts.

The challenge specialized search services need to solve is to educate people how to conduct better searches. More than 90% of people conducting searches don't go beyond the first two search page results. And, only 3% of searchers use quote marks to search an exact phrase. Finding that needle in the haystack isn't all that hard if you know how and where to look.

Dan McKillen is president of the HealthDay news service

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...